

Monthly Portfolio Update

*Amundi Funds II – Pioneer Strategic Income**

30 April 2018

BOND

COMMENTARY

Market Review

Developed financial markets stabilised, while Emerging Markets (EM) sold off in the wake of higher oil prices and higher interest rates over the month. Developed equity delivered modestly positive returns, while Investment Grade (IG) credit markets slightly outperformed governments, benefitting from a 7% increase in oil prices, as well as from reduced trade tensions, better than expected first quarter U.S. GDP growth, positive earnings outcomes, with almost 75% of companies exceeding estimates, and with lower volatility. Despite these positive factors, however, performance within these markets was negative affected by rising rates and inflation. High Yield (HY) markets outperformed, benefitting from significant energy exposure, their higher all-in yield, and a benign default outlook. EM suffered from higher U.S. rates, and a rally in the U.S. Dollar.

Rising inflation expectations, spurred by higher oil prices and more hawkish Fed minutes resulted in a broad sell-off in U.S. Treasuries across the curve. Two-year Treasury yields rose from 2.27% to 2.49%, while the 10-year yield rose from 2.74% to 2.94%, after peaking at 3.03% on April 25. German Bund yields followed in sympathy. Structured credit outperformed U.S. Treasuries, benefitting from a decline in volatility and demand for risk assets.

Agency MBS recouped almost half of their underperformance year-to-date in April, with a 0.2% excess return relative to U.S. Treasuries. Ginnie Maes outperformed as rates rose and as regulators cracked down on aggressive servicers who were generating a high churn of VA loan pools.

In addition, high coupon collateral outperformed. CMBS and ABS enjoyed excess returns similar to agency MBS. IG corporates eked out a small positive excess return for the month, as the benefit of generally strong earnings reports was offset by concerns around higher sector leverage, and higher issuance driven by increased mergers and acquisition activity in the wake of lower demand from non-U.S. investors. HY markets on the other hand enjoyed strong performance, delivering strong excess return of

over 1% and an absolute return of 0.7%, as spreads narrowed from 372 to 346 bps.

EM debt fell victim to higher rates, with USD EM sovereigns returning -1.5% and corporates, -0.7%. Local EM debt, which had held up better than USD-denominated debt, underperformed, as the U.S. Dollar rallied. The U.S. Dollar rose 2.0% over the month, as investors priced in greater policy divergence between a more hawkish Fed and more dovish global developed central banks. The U.S. Dollar rose 1.8% vs. the Euro and 2.7% vs. the Yen.

Portfolio Review

Duration position and sector allocation accounted for Portfolio outperformance relative to the benchmark (Bloomberg Barclays U.S. Universal Index) over the month.

Positive:

- The relative short duration position of 1.5 years contributed to outperformance, as rates rose across the curve. Both the short duration position within the U.S. as well as the short German Bund/Bobl position outperformed.
- Portfolio returns benefitted from sector allocation, primarily reflecting the benefit of the 3.7% TIPS exposure and the underweight to nominal U.S. Treasuries. 30-year breakeven rates rose from 2.07% to 2.19%, as wage inflation and oil prices surprised to the upside.
- The Portfolio was also helped by the lower relative quality of the Portfolio's holdings within Industrials, particularly the overweight to HY issues, as HY markets outperformed.

Negative:

- The Portfolio was hurt by its currency exposures, particularly by the 3.1% exposure to the Swedish Krona. With its twin surpluses and stronger relative GDP growth, we anticipated that the Rijkbank would raise

rates more quickly than the ECB. Instead, with relatively contained inflation, the Rijksbank kept rates on hold, and the U.S. Dollar outperformed the Krona by 4.6%.

Outlook

Despite recent disappointing data out of the Eurozone, we believe that growth may be strong for the U.S. and globally in 2018, buoyed by fiscal stimulus in the U.S. and strong global domestic demand. We believe U.S. GDP growth could accelerate to almost 3% over the year, benefitting from significant tax cuts, deregulation, and stronger fixed investment spending. We believe solid employment and income growth should continue to support consumption and the housing market. Higher corporate profits, benefitting from strong global growth, tax cuts, and the 100% expensing of fixed investment, may also support increased fixed investment.

Globally, we continue to believe the Eurozone and Japan should also enjoy strong growth, benefitting from still supportive monetary policy. Eurozone growth may be lower than that achieved in 2017, as exports could suffer from the lagged effects of a stronger Euro. In addition, political risk, has risen in Europe, due to the triumph of populists in the Italian elections, as well as union resistance to Macron's implementation of labour reforms in France. While we expect that China's growth might moderate in light of its goals to rein in credit growth, we believe a modest decline in China's growth should not disrupt overall Asia or global GDP growth.

Global growth could moderate, however, in the face of President Trump's more aggressive protectionist trade policy. While the U.S. and China are negotiating trade imbalances, he has taken a much more vocal stand on trade than expected, and China has responded in kind.

We continue to believe that inflation could surprise to the upside on a number of fronts in 2018 and that the FOMC may be behind the curve in raising rates. Nascent signs of wage growth acceleration, service inflation, tighter labour markets in key industries such as homebuilding, and more restrictive immigration policies should contribute to higher price levels in the coming year. In addition, producer price indices are already increasing, on the heels of higher oil and metals prices. Fiscal stimulus, including the tax cuts

and higher spending from the budget, has the potential to further fuel inflation.

The Portfolio continues to be positioned for rising interest rates, and a solid economy. The Portfolio holds the following positions:

- Overweight to diverse credit sectors, underweight to U.S. Treasuries. Most U.S. government debt is unattractive, while credit sectors could benefit from stronger growth, lower taxes, and less regulation.
- The Portfolio holds a relative short duration position compared to its benchmark. We believe the market may be behind the curve, given solid GDP growth, and little slack in the labour market. At 1.9%, core PCE has already reached the Fed's year-end target. With the unemployment at 3.9%, we anticipate that continued wage inflation will help drive core PCE to higher levels through the year.
- We hold long-duration TIPS, which we believe have the potential to help protect the Portfolio should inflation surprise to the upside. While breakevens for 30-year U.S. Treasuries now stand at almost 2.2%, we believe inflation expectations could overshoot; in addition, these levels remain below long-term averages.
- The Portfolio has modestly reduced its agency MBS position, resulting in a small underweight to the market; including the 12% in non-agency MBS, it continues to remain significantly overweight to the RMBS sector. Fundamentals within the housing market remain positive, spurred by strong GDP growth and employment, and still reasonable mortgage rates. In addition, we believe that agency MBS offer investors reasonable value at current spreads. While certain investors are concerned about the increased net supply of approximately \$400 billion forecast for 2018, we believe that the market has already priced in this forecast (which we witnessed earlier in 2017 when the Fed first announced the taper plan). The FOMC has been fully transparent in setting forth its tapering programme with respect to both U.S. Treasuries and agency MBS. Moreover, agency MBS already extended duration in the fourth quarter of 2016, in response to higher rates, and we do not foresee significant extension risk going forward. High quality non-agency RMBS remain attractive, with pristine credit metrics and trade approximately 1.0 point behind agency MBS, translating into a spread pickup of 20 bps vs. agency MBS.

- We believe structured securities including ABS and CMBS generally offer more attractive relative value than corporates, and find attractive opportunities within non-Index ABS issues.
- The Portfolio holds a near index weight in IG corporates, as the team added modestly to exposure over the past few months as spreads had widened. The Portfolio also continues to hold an overweight to HY corporates. Spreads in broad IG corporates now stand near fair value; but these spreads reflect lower average quality and overall longer duration relative to their historical levels. Leverage in IG corporates is significantly higher than in the past, with 23% of the market trading at greater than 4X leverage, compared to 11% five years ago. Tighter spreads and higher leverage is counterbalanced by strong fundamentals. We continue to believe, however, that corporates face greater downside risk than agency MBS, in a higher volatility environment that may result from a negative outcome on trade policy, an unexpected change in central bank policies or from an unexpected slowdown in global growth.
- Within corporates, we continue to hold an overweight to Financials in banks, insurance and REITS. We hold exposure to European banks, and reduced exposure to U.S. banks, based on more attractive relative value and the positive outlook for GDP growth in the Eurozone. More generally, we believe the banking, insurance and REITS offer attractive relative value and may perform well, despite a rising rate environment. While spreads are modestly lower than the broad corporate benchmarks, Financials offer lower event risk of share repurchases or credit impairment due to M&A activity. Banks are currently focused on improving capital ratios to meet regulatory requirements. Banks should also benefit from rising global yields and steepening yield curves.
- We continue to hold an overweight to the Energy midstream sub-sector, a sector that shows relatively less sensitivity to oil price volatility. We expect continued spread tightening in the space, which remains one of the wider-trading subsectors in IG. OPEC's extension of production cuts should help offset increased production from U.S. shale producers, and the global demand outlook has improved.
- The Portfolio includes certain EM exposures at a near-Index weight. We prefer countries that have undertaken important structural reforms, such as India, Indonesia, and Argentina. Notably, valuations in select EM have become more extended, although we believe they generally offer solid fundamentals.
- We believe the U.S. Dollar may be range-bound going forward, or may modestly appreciate should Eurozone growth disappoint. Given the higher volatility associated with currencies, and extended valuations across a number of currencies, we may reduce non-Dollar exposure going forward.

Important Information

On the 16 February 2018, Pioneer Funds was renamed Amundi Funds II. Prior to 16 February 2018 the name of the sub-fund was with the prefix "Pioneer Funds".

This material is provided to Professional Clients, including financial intermediaries, and is not intended for and should not be provided to the public.

This document contains information about investment services provided by Amundi group companies or undertakings for collective investment in transferable securities (the "Funds") established under the laws of Luxembourg and authorised for public distribution by the Commission de Surveillance du Secteur Financier. The management company of

- Amundi Funds, Amundi Funds II, Amundi SICAV II, Amundi Fund Solutions and First Eagle Amundi is Amundi Luxembourg S.A., 5, allée Scheffer, L-2520 Luxembourg;
- CPR Invest is CPR Asset Management, 90 Boulevard Pasteur, 75015 Paris, France;
- KBI Institutional ICAV is KBI Global Investors Ltd., 2 Harbourmaster Place, International Financial Services Centre, Dublin 1, Ireland.

This material is information purposes only, is not a recommendation, financial analysis or advice, and does not constitute a solicitation, invitation or offer to purchase or sell any the Funds or services described herein in any jurisdiction where such offer, solicitation or invitation would be unlawful.

This material has not been submitted for regulatory approval and is solely for issue in permitted jurisdictions and to persons who may receive it without breaching applicable legal or regulatory requirements. The information contained in this document is confidential and shall not, without prior written approval of Amundi Ireland Limited ("Amundi"), be copied, reproduced, modified, or distributed, to any third person or entity in any country.

The Funds described in this document may not be available to all investors and may not be registered for public distribution with the relevant authorities in all countries.

Investment involves risk. **Past performance is not a guarantee or indication of future results.** Investment return and the principal value of an investment in the Funds or other investment product may go up or down and may result in the loss of the amount originally invested. All investors should seek professional advice prior to any investment decision, in order to determine the

risks associated with the investment and its suitability. It is the responsibility of investors to read the legal documents in force in particular the current prospectus for each Fund. Subscriptions in the Funds will only be accepted on the basis of their latest prospectus and/or the Key Investor Information Document (“KIID” available in local language in EU countries of registration) which, together with the latest annual and semi-annual reports may be obtained, free of charge, at the registered office of Amundi Luxembourg S.A. or at www.amundi.lu. In Italy, this documentation is available at www.amundi.it. Information relating to costs and charges of the Funds may be obtained from the KIID.

The performance data do not take account of the commissions and costs incurred on the issue and redemption of units of the Funds.

In **EEA** Member States, the content of this document is approved by Amundi for use with Professional Clients (as defined in EU Directive 2004/39/EC) only and shall not be distributed to the public. Amundi Ireland Limited is authorised and regulated by the Central Bank of Ireland. KBI Institutional ICAV is a collective investment scheme established under Irish law. Société Générale, Dublin Branch 3rd Floor, IFSC House, IFS, Dublin 1 is the facilities agent for those sub-funds of Amundi Funds, Amundi Funds II, First Eagle registered in Ireland.

In the **UK**, this document is approved for distribution by Amundi Asset Management London Branch), 41 Lothbury, London, EC2R 7HF. Amundi Asset Management is a portfolio management company authorised by the Autorité des Marchés Financiers in France and its London Branch is subject to limited regulation by the UK Financial Conduct Authority. Further information of this authorisation is available on request. Amundi Funds SICAV, First Eagle Amundi SICAV, CPR Invest SICAV, KBI Institutional ICAV and Amundi SICAV II are recognised schemes for the purposes of Section 264 of the Financial Services and Markets Act 2000 (the “FSMA”) of the UK and can be promoted and sold direct to the public in the United Kingdom subject to compliance with the FSMA and applicable regulations made thereunder. Amundi Funds II is an unregulated collective investment scheme under (“FSMA”). Potential investors in the UK should be aware that none of the protections afforded by the UK regulatory system will apply to an investment any of the Funds and that compensation will not be available under the UK Financial Services Compensation Scheme. This document is addressed only to those persons in the UK falling within one or more of the following exemptions from the restrictions in s 238 FSMA:

- authorised firms under FSMA and certain other investment professionals falling within article 14 of the FSMA (Promotion of Collective Investment Schemes) (Exemptions) Order 2001, as amended (the “CIS Order”) and their directors, officers and employees acting for such entities in relation to investment;
- high value entities falling within article 22 CIS Order and their directors, officers and employees acting for such entities in relation to investment;
- other persons who are in accordance with the Rules of the FCA prior to 1 November 2007 classified as Intermediate Customers or Market Counterparties or on or thereafter classified as Professional Clients or Eligible Counterparties.

The distribution of this document to any person in the UK not falling within one of the above categories is not permitted by Amundi Asset Management London Branch and may contravene FSMA. No person in the UK falling outside those categories should rely or act on it for any purposes whatsoever.

In **Switzerland**, this document is for Qualified Investors (as defined in Swiss Collective Investment Schemes Act of 23 June

2006 as amended or supplemented) use only and shall not be distributed to the public.

The Representative and Paying Agent for Funds registered for distribution in Switzerland are, in respect of Amundi Funds II: BNP Paribas Securities Services, Zurich Branch, Selnaustrasse 16, 8002 Zurich Amundi Funds and First Eagle Amundi: Representative - CACEIS (Switzerland) SA and Paying Agent - CACEIS Bank, Nyon Branch both at 35 Route de Signy, Case postale 2259, CH-1260 Nyon; KBI Institutional Fund SICAV: Representative – ACOLIN Fund Services AG, Affolternstrasse 56, CH-8050 Zurich and Paying Agent – NPB Neue Privat Bank AG, Limmatquai 1, CH-8001 Zurich. Free copies of the prospectus, key investor information documents, annual and semi-annual reports, management regulations and other information are available at the representative’s address shown above.

Amundi Suisse SA has been authorized in Switzerland to distribute the Funds. Amundi Suisse SA. Amundi Suisse SA receives from Amundi Luxembourg S.A. or other Amundi group entities, compensation under article 34 al. 2bis of the OPCC (Ordonnance sur les placements collectifs de capitaux). Such compensation may constitute a part of the management fees stated in the prospectus of the Funds and further information may be obtained upon written request to Amundi Suisse S.A., 6-8 rue de Candolle 1205 Genève Suisse.

In **France**, a free prospectus is available from Amundi Asset Management, 90 boulevard Pasteur -75015 Paris - France - 437 574 452 RCS Paris France or from the centralisateur of the Funds which in the case of Amundi Funds SICAV and CPR Invest SICAV is CACEIS Bank SA, 1-3 place Valhubert, 75013 Paris and in the case of Amundi Funds II and First Eagle Amundi SICAV is Société Générale, 29 Boulevard Haussmann, 75008 Paris.

In Germany, for additional information on the Fund, a free prospectus may be requested from Amundi Deutschland GmbH, Arnulfstr. 124-126 80636 Munich, Germany (Tel. +49.89.99.226.0).

In **Austria** the paying agents for Funds registered for public distribution in are, in respect of Amundi Funds II and Amundi Fund Solutions: UniCredit Bank Austria AG, Schottengasse 6-8, A-1010 Vienna Amundi Funds: Meindl Bank Aktiengesellschaft, Bauernmarkt 2, A-1010 Vienna; First Eagle Amundi: Société Générale, Vienna Branch, Prinz Eugen Strasse 8 - 10/5/Top 11, A-1040 Vienna; CPR Invest: Raiffeisen Bank International AG, Am Stadtpark 9, A-1030 Wien; and KBI Institutional ICAV: Erste Bank der oesterreichischen Sparkassen AG, Am Belvedere 1, A-1100 Vienna.

In **Spain**, the Funds are foreign undertakings for collective investment registered with the CNMV and numbered Amundi Funds II (226); Amundi S.F (493); Amundi Fund Solutions (1333); Amundi Funds (61) First Eagle Amundi (111); CPR Invest (1564); and KBI Institutional ICAV (1248). Any investment in the Funds or their respective sub-funds must be made through a registered Spanish distributor. Amundi Iberia SGIC, SAU, is the main distributor of the Funds in Spain, registered with number 31 in the CNMV’s SGIC registry, with address at Pº de la Castellana 1, Madrid 28046. A list of all Spanish distributors may be obtained from the CNMV at www.cnmv.es. Units may only be acquired on the basis of the most recent prospectus, key investor information document and further current documentation, which may be obtained from the CNMV. In Chile and Peru, this document is approved for use by Administradora de Fondos de Pensiones/Pension Fund Administrators and other institutional investors.

In **Mexico**, this document is approved for use with institutional investors. It may not be distributed to third parties or to the public.

For Professional Clients Only

*Prior to 16 February 2018, Pioneer Funds – Strategic Income

In **Singapore**, this document is provided solely for the use of distributors and financial advisors only and is not to be distributed to the retail public. Distribution occurs through Amundi Singapore Ltd, 168 Robinson Road, #24-01, Capital Tower, Singapore 068912. This document contains information about certain sub-funds of Amundi Funds and First Eagle Amundi SICAV which may be registered as recognised schemes in Singapore under the Securities and Futures Act (Cap. 289) of Singapore ("SFA"), or notified as restricted schemes under the Sixth Schedule to the Securities and Futures (Offers of Investments) (Collective Investment Schemes) Regulations 2005, while certain sub-funds of Amundi Funds II are restricted schemes. For the sub-funds or relevant share/unit classes notified as restricted schemes in Singapore, such sub-funds or relevant share/unit classes are not authorised or recognised by the Monetary Authority of Singapore ("MAS") and are not allowed to be offered to the Singapore retail public. Accordingly, this document and the material contained within, may not be circulated or distributed, nor may the relevant shares/units be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 304 of the SFA, (ii) to a relevant person pursuant to Section 305(1), or any person pursuant to Section 305(2), and in accordance with the conditions specified in Section 305 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. In other Asian jurisdictions, for use by licensed intermediaries only and not to be distributed to the public.

This information is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities or services in **the United States** or in any of its territories or possessions subject to its jurisdiction to or for the benefit of any U.S. Person (as defined in the prospectus of the Funds). The Funds have not been registered in the United States under the Investment Company Act of 1940 and units of the Funds are not registered in the United States under the Securities Act of 1933. This document is not intended for and no reliance can be placed on this document by persons falling outside of these categories in the above mentioned jurisdictions.

In jurisdictions other than those specified above, this document is for the sole use of the professional clients and intermediaries to whom it is addressed. It is not to be distributed to the public or to other third parties and the use of the information provided by anyone other than the addressee is not authorised.

This material, is based on sources that Amundi considers to be reliable at the time of publication. Data, opinions and analysis may be changed without notice. Amundi accepts no liability whatsoever, whether direct or indirect, that may arise from the use of information contained in this material. Amundi can in no way be held responsible for any decision or investment made on the basis of information contained in this material

© 2018 Morningstar. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar; (2) may not be copied or redistributed; (3) do not constitute investment advice; (4) are provided solely for informational purposes; (5) are not warranted to be complete, accurate or timely; and (6) may be drawn from fund data published on various dates. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don't make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The Funds or securities referred to herein are not sponsored, endorsed, or promoted by MSCI, and MSCI bears no liability with respect to any such Funds or securities or any index on which such Funds or securities are based. The offering documents of the Funds contain a more detailed description of the limited relationship MSCI has with Amundi and any relevant Funds.

Date of publication: 10 May 2018.

Document ID: 496123